PT - JOURNAL ARTICLE AU - Jin Kyun Park AU - Christopher A. Mecoli AU - Helene Alexanderson AU - Malin Regardt AU - Lisa Christopher-Stine AU - María Casal Domínguez AU - Ingrid de Groot AU - Catherine Sarver AU - Ingrid E. Lundberg AU - Clifton O. Bingham 3rd AU - Yeong Wook Song TI - Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study AID - 10.3899/jrheum.161252 DP - 2017 Aug 01 TA - The Journal of Rheumatology PG - jrheum.161252 4099 - http://www.jrheum.org/content/early/2017/07/26/jrheum.161252.short 4100 - http://www.jrheum.org/content/early/2017/07/26/jrheum.161252.full AB - Objective To define a set of core patient-reported domains and respective instruments for use in idiopathic inflammatory myopathies (IIM). Previously, we reported a systematic literature review on patient-reported outcomes (PRO) in IIM followed by conducting international focus groups to elicit patient perspectives of myositis symptoms and effects. Methods Based on qualitative content analysis of focus groups, an initial list of 26 candidate domains was constructed. We subsequently conducted an international modified Delphi survey to identify the importance of each of the 26 domains. Participants were asked to rate each domain on a scale of 0–10 (0 = not important, 10 = very important). Results In this first round of the Delphi survey, 643 patients participated from the United States (n = 543), Sweden (n = 49), and South Korea (n = 51). Of the 26 domains, 19 (73%) were rated of high importance (≥ 7/10). The top 5 domains were muscle symptoms, fatigue, interactions with healthcare, medication side effects, and pain. During Outcome Measures in Rheumatology (OMERACT) 2016, we discussed the goal for ultimate reduction in the number of domains and the importance of considering representation of healthcare providers from other specialties, caregivers, representatives of pharmaceutical industries, and regulatory authorities in the next rounds of Delphi to represent broader perspectives on IIM. Conclusion Further prioritization and a reduction in the number of domains will be needed for the next Delphi. At the next biennial OMERACT meeting, we aim to present and seek voting on a Myositis Preliminary PRO Core Set to enable ultimate measure selection and development.